KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $198

KeyBanc维持ICU医疗(ICUI.US)买入评级，上调目标价至198美元

moomoo资讯 · 10/15 19:31 · 评级/大行评级

KeyBanc analyst Brett Fishbin maintains $ICU Medical (ICUI.US)$ with a buy rating, and adjusts the target price from $147 to $198.

According to TipRanks data, the analyst has a success rate of 94.1% and a total average return of 22.3% over the past year.

AnalystRecentRatingAutoNews_202793_20241015_b29bdbba70249ee55c0b8e740af7a70646288adc_1729071031743469_mm_en

Furthermore, according to the comprehensive report, the opinions of $ICU Medical (ICUI.US)$'s main analysts recently are as follows:

The firm is encouraged by considerable advancements made thus far in the year, showcasing enhanced operational stability. With guidance remaining on the conservative side, there is a belief in the potential for sustained outperformance moving into the latter half of 2024. Additionally, there are several factors that could drive further upside in 2025.
ICU Medical is recognized for its robust usage environment and a commanding presence in the expanding market for IVs and disposables. Despite these strengths, analysis and industry feedback indicate that the company is not expected to capture significant market share from its main competitors, which results in projections that align with the general consensus.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

KeyBanc分析师Brett Fishbin维持$ICU医疗 (ICUI.US)$买入评级，并将目标价从147美元上调至198美元。

根据TipRanks数据显示，该分析师近一年总胜率为94.1%，总平均回报率为22.3%。

AnalystRecentRatingAutoNews_202793_20241015_b29bdbba70249ee55c0b8e740af7a70646288adc_1729071031743469_mm_sc

此外，综合报道，$ICU医疗 (ICUI.US)$近期主要分析师观点如下：

该公司对今年迄今为止取得的重大进展感到鼓舞，这表明运营稳定性得到增强。由于指导方针仍然偏向保守，人们相信到2024年下半年，业绩有可能持续跑赢大盘。此外，有几个因素可能会推动2025年进一步上涨。
ICU Medical因其强大的使用环境以及在不断扩大的IV和一次性用品市场中占据主导地位而获得认可。尽管有这些优势，但分析和行业反馈表明，预计该公司不会从主要竞争对手手中夺取大量市场份额，这导致预测与普遍共识一致。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $198

KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $198

风险及免责提示

声明